Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Identifieur interne : 000C47 ( Ncbi/Curation ); précédent : 000C46; suivant : 000C48Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
Auteurs : N K Ayisi [Ghana]Source :
- East African medical journal [ 0012-835X ] ; 1995.
Descripteurs français
- KwdFr :
- Antiviraux (pharmacologie), Culture virale, Didéoxyinosine (pharmacologie), Effet cytopathogène viral (), Ghana, Humains, Tests de sensibilité microbienne, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (pathogénicité), Zalcitabine (pharmacologie), Évaluation préclinique de médicament.
- MESH :
- pathogénicité : VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2).
- pharmacologie : Antiviraux, Didéoxyinosine, Zalcitabine.
- Culture virale, Effet cytopathogène viral, Ghana, Humains, Tests de sensibilité microbienne, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2), Évaluation préclinique de médicament.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Antiviral Agents (pharmacology), Cytopathogenic Effect, Viral (drug effects), Didanosine (pharmacology), Drug Evaluation, Preclinical, Ghana, HIV-1 (classification), HIV-1 (drug effects), HIV-1 (pathogenicity), HIV-2 (classification), HIV-2 (drug effects), HIV-2 (pathogenicity), Humans, Microbial Sensitivity Tests, Virus Cultivation, Zalcitabine (pharmacology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Didanosine, Zalcitabine.
- geographic : Ghana.
- classification : HIV-1, HIV-2.
- drug effects : Cytopathogenic Effect, Viral, HIV-1, HIV-2.
- pathogenicity : HIV-1, HIV-2.
- Drug Evaluation, Preclinical, Humans, Microbial Sensitivity Tests, Virus Cultivation.
Abstract
The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.
PubMed: 8904046
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000697
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000697
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000697
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000C47
Links to Exploration step
pubmed:8904046Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title><author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name><affiliation wicri:level="4"><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation><orgName type="university">Université du Ghana</orgName><country>Ghana</country><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8904046</idno><idno type="pmid">8904046</idno><idno type="wicri:Area/PubMed/Corpus">000697</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000697</idno><idno type="wicri:Area/PubMed/Curation">000697</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000697</idno><idno type="wicri:Area/PubMed/Checkpoint">000697</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000697</idno><idno type="wicri:Area/Ncbi/Merge">000C47</idno><idno type="wicri:Area/Ncbi/Curation">000C47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.</title><author><name sortKey="Ayisi, N K" sort="Ayisi, N K" uniqKey="Ayisi N" first="N K" last="Ayisi">N K Ayisi</name><affiliation wicri:level="4"><nlm:affiliation>Virology Unit, Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.</nlm:affiliation><orgName type="university">Université du Ghana</orgName><country>Ghana</country><placeName><settlement type="city">Accra</settlement><settlement type="town">Legon (Ghana)</settlement><region type="region">Région du Grand Accra</region></placeName></affiliation></author></analytic><series><title level="j">East African medical journal</title><idno type="ISSN">0012-835X</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (pharmacology)</term><term>Cytopathogenic Effect, Viral (drug effects)</term><term>Didanosine (pharmacology)</term><term>Drug Evaluation, Preclinical</term><term>Ghana</term><term>HIV-1 (classification)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (pathogenicity)</term><term>HIV-2 (classification)</term><term>HIV-2 (drug effects)</term><term>HIV-2 (pathogenicity)</term><term>Humans</term><term>Microbial Sensitivity Tests</term><term>Virus Cultivation</term><term>Zalcitabine (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term><term>Culture virale</term><term>Didéoxyinosine (pharmacologie)</term><term>Effet cytopathogène viral ()</term><term>Ghana</term><term>Humains</term><term>Tests de sensibilité microbienne</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) ()</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (pathogénicité)</term><term>Zalcitabine (pharmacologie)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Didanosine</term><term>Zalcitabine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Didéoxyinosine</term><term>Zalcitabine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Microbial Sensitivity Tests</term><term>Virus Cultivation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Culture virale</term><term>Effet cytopathogène viral</term><term>Ghana</term><term>Humains</term><term>Tests de sensibilité microbienne</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The cytopathicity and susceptibility of prototype HIV-1 [HTLVIIIB] and Ghanaian HIV isolates [GH1, GH2, GH3] to inhibition by ddCyd and ddIno were determined by the tetrazolium-based colorimetric method. HIV-1 [HTLVIIIB] caused the most cytopathic effect followed by HIV-2 [GH2]. At low MOI, HIV-2 [GH1] was more cytopathic than HIV-1 [GH3] but the reverse was true at high MOI. Using EC90 concentrations for comparison at similar cytopathicities, both HIV-1 [HTLVIIIB] and HIV-1 [GH3] which belong to prototype HIV-1 group, were effectively inhibited by one or both drugs. In contrast, HIV-2 [GH1] which belongs to prototype HIV-2 group, and especially, the highly divergent HIV-2 [GH2] which belongs to HIV-2b group were relatively resistant to inhibition by ddCyd and ddIno.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000C47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:8904046
|texte= Differential cytopathicity and susceptibility of Ghanaian highly divergent HIV-2 -GH2-, prototype HIV-2 -GH1-, and prototype HIV-1 -GH3- to inhibition by ddCyd and ddIno.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:8904046" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |